vorasidenib
servier
['vorasidenib', 'indigo']
vorasidenib improved pfs outcomes for patients with grade 2 idh-mutant glioma vs placebo, according to findings from the phase 3 indigo trial #asco23 
Capturing the voice of nursing professionals in the oncology news landscape.